Table 2.
Sustained Virologic Response (SVR) with Interferon-Free Direct-Acting Antivirals (DAAs) and Outcome in Patients with HCV-Related HCC Who Have Achieved SVR
| Author/Publication Year | Country/Region | DAA-Treated HCC Patients (n) | SVR in HCC Patients | SVR in Patients with Active HCC | SVR in Patients with Inactive HCC | SVR in HCC Patients with LC | SVR in HCC Patients Without LC | 5-Year Overall Survival | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Beste et al 201781 | USA | 482 | 74.4% †91.1% in the non-HCC group †94.0% in the HCC/LT group |
73.0% †87.9% in non-HCC patients with LC |
82.5% †92.4% in non-HCC patients without LC |
||||||
| Ji et al 201968 | 15 countries from USA, Japan, Italy, Egypt, France, China, Spain, United Kingdom, Germany, Switzerland, Romania, Belgium, Australia, Canada, and Poland | 2581 *Including active HCC patients (n=277) and inactive HCC patients (n=2304) |
89.6% †93.3% in the non-HCC group (P=0.0012) |
73.1% | 92.6% | ||||||
| Ogawa et al 202062 | Hong Kong, Japan, South Korea, and Taiwan | 436 *Including active HCC patients (n=55), inactive HCC patients (n=366) and unknown(n=15) |
92.7% †95.0% in the non-HCC group (P=0.16) |
85.5% | 93.7% | ||||||
| Dang et al 202092 | USA, Japan, South Korea, and Taiwan | 321 *All achieved SVR *Propensity Score Matching patients |
87.78% †66.05% in DAA-untreated HCC patients (P <0.001) |
||||||||
| He et al 202090 | 13 countries from France, Canada, US, Italy, UK, NZ, Spain, Egypt, Germany, Japan, Taiwan, Poland, and China | 361 | 82.5% †90.4% in the curative HCC management group |
||||||||
| Chen et al 202191 | Taiwan | 1473 *Including active HCC patients (n=328) and inactive HCC patients (n=1145) |
96.5% †98.5% in the non-HCC group (P <0.001) |
93% | 97.6% | Active HCC | Inactive HCC | Active HCC | Inactive HCC | ||
| Naïve LC | 91.6% | 97.7% | 96.3% | 96.3% | |||||||
| Prior treatment experience | 92.2% | 98.2% | 98.1% | 96.6% | |||||||
Notes: This table includes only studies with a number of DAA-treated HCC patients > 100. *Comments on study population or/and method, †Analysis in subgroup.
Abbreviations: DAA, direct-acting antivirals; SVR, sustained virologic response; HCC, hepatocellular carcinoma; LC, liver cirrhosis; LT, liver transplantation; HR, hazard ratio; CI, confidence interval.